Condition: Alzheimer Disease, Early Onset · Sponsor: Denali Therapeutics Inc.
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment, or mild AD with biomarker evidence of amyloid positivity. Note: In the Netherlands, this study includes an open-label extension.
This description comes directly from the study's public registry record.
Clinical Trials at Denali Therapeutics · Email: · clinical-trials@dnli.com
Always discuss trial participation with your own doctor first.
| Clinical Site(s) | 's-Hertogenbosch, Netherlands | Recruiting |
| Clinical Site(s) | Amsterdam, Netherlands | Recruiting |
| Clinical Site(s) | Zwolle, Netherlands | Recruiting |
| Clinical Site(s) | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07328451